For the quarter ended September 2026, United Therapeutics (UTHR Quick QuoteUTHR - Free Report) reported revenue of $832.5 million, up 4.1% over the same period last year. EPS came in at $5.71, compared to $7.16 in the year-ago quarter.

The reported revenue represents a surprise of +6.28% over the Zacks Consensus Estimate of $783.33 million. With the consensus EPS estimate being $5.85, the EPS surprise was -2.39%.

While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.

As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.

Here is how United Therapeutics performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

• Revenues- Unituxin: $52.3 million versus the four-analyst average estimate of $49.62 million. The reported number represents a year-over-year change of +9.2%.
• Revenues- Adcirca: $4.5 million compared to the $7.56 million average estimate based on four analysts. The reported number represents a change of -53.6% year over year.
• Revenues- Tyvaso: $503.8 million compared to the $465.98 million average estimate based on four analysts. The reported number represents a change of +5.4% year over year.
• Revenues- Remodulin: $122 million versus the four-analyst average estimate of $122.09 million. The reported number represents a year-over-year change of -3.1%.
• Revenues- Orenitram: $145 million versus $133.26 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +10.6% change.
• Revenues- Other products: $4.9 million versus $6.85 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a -29% change.
• Revenues- Nebulized Tyvaso: $125.3 million versus the two-analyst average estimate of $151.85 million. The reported number represents a year-over-year change of -11.6%.
• Revenues- Tyvaso DPI: $378.5 million versus the two-analyst average estimate of $321.57 million. The reported number represents a year-over-year change of +12.6%.

View all Key Company Metrics for United Therapeutics here>>>

Shares of United Therapeutics have returned +11% over the past month versus the Zacks S&P 500 composite's -2% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.